000 -LEADER |
fixed length control field |
03022cam a2200445 i 4500 |
001 - CONTROL NUMBER |
control field |
17904169 |
003 - CONTROL NUMBER IDENTIFIER |
control field |
KPN |
005 - DATE AND TIME OF LATEST TRANSACTION |
control field |
20211006155806.0 |
008 - FIXED-LENGTH DATA ELEMENTS--GENERAL INFORMATION |
fixed length control field |
130930s2014 nyua b 001 0 eng |
010 ## - LIBRARY OF CONGRESS CONTROL NUMBER |
LC control number |
2013039646 |
020 ## - INTERNATIONAL STANDARD BOOK NUMBER |
International Standard Book Number |
9781451655667 (hardback) |
|
International Standard Book Number |
9781451655674 (trade paperback) |
|
Canceled/invalid ISBN |
9781451655698 (ebook) |
040 ## - CATALOGING SOURCE |
Original cataloging agency |
DNLM/DLC |
Transcribing agency |
DLC |
Description conventions |
rda |
Modifying agency |
DLC |
042 ## - AUTHENTICATION CODE |
Authentication code |
pcc |
050 00 - LIBRARY OF CONGRESS CALL NUMBER |
Classification number |
RA401.A3 |
Item number |
W37 2014 |
060 10 - NATIONAL LIBRARY OF MEDICINE CALL NUMBER |
Classification number |
QV 736 AA1 |
082 00 - DEWEY DECIMAL CLASSIFICATION NUMBER |
Classification number |
338.4/76151 |
Edition number |
23 |
100 1# - MAIN ENTRY--PERSONAL NAME |
Personal name |
Werth, Barry, |
Relator term |
author. |
245 14 - TITLE STATEMENT |
Title |
The antidote : |
Remainder of title |
inside the world of new pharma / |
Statement of responsibility, etc. |
Barry Werth. |
250 ## - EDITION STATEMENT |
Edition statement |
First Simon & Schuster hardcover edition. |
260 ## - PUBLICATION, DISTRIBUTION, ETC. |
Place of publication, distribution, etc. |
New York |
Name of publisher, distributor, etc. |
Simon & Schuster |
Date of publication, distribution, etc. |
2014 |
264 #1 - PRODUCTION, PUBLICATION, DISTRIBUTION, MANUFACTURE, AND COPYRIGHT NOTICE |
Place of production, publication, distribution, manufacture |
New York : |
Name of producer, publisher, distributor, manufacturer |
Simon & Schuster, |
Date of production, publication, distribution, manufacture, or copyright notice |
2014. |
300 ## - PHYSICAL DESCRIPTION |
Extent |
x, 435 pages : |
Other physical details |
illustration ; |
Dimensions |
25 cm |
336 ## - CONTENT TYPE |
Content type term |
text |
Source |
rdacontent |
337 ## - MEDIA TYPE |
Media type term |
unmediated |
Source |
rdamedia |
338 ## - CARRIER TYPE |
Carrier type term |
volume |
Source |
rdacarrier |
504 ## - BIBLIOGRAPHY, ETC. NOTE |
Bibliography, etc. note |
Includes bibliographic references (pages 401-416) and index. |
520 ## - SUMMARY, ETC. |
Summary, etc. |
"This is the Moneyball of the pharma world, the story of one drug company's quest to transform the pharmaceutical industry and a deeply revealing look into a world where breakneck capitalism meets life-saving medicine.The $325 billion-a-year pharmaceutical business is America's most challenging and one of its most profitable. It is tougher in just about every way than any other enterprise: from the towering biological risks inherent in its mission to treat disease; to the thirty-to-one failure rate in bringing out a successful medicine after a candidate clears all the hurdles to get to human testing; to the billion-dollar-plus cost of ramping up a successful product; to operating in the worlds most highly regulated industry with the possible exception of nuclear power. The Antidote tells the story of Vertex, a maverick drug company led by the charismatic Joshua Boger and a small group of entrepreneurial young scientists who broke off from Merck when it was the world's best drug maker, indeed the most admired business in America because they thought they could make drugs better. Building upon his widely praised The Billion-Dollar Molecule, Barry Werth captures the full scope of Vertex's twenty-five-year drive to liver breakthrough medicines and transform the drug industry. The Antidote draws upon unprecedented inside reporting spanning more than two decades to provide a groundbreaking close-up of Vertex's inner workings and the ferocious but indispensable world it inhabits"--Provided by publisher. |
546 ## - LANGUAGE NOTE |
Language note |
In English |
610 22 - SUBJECT ADDED ENTRY--CORPORATE NAME |
Corporate name or jurisdiction name as entry element |
Vertex Pharmaceuticals Incorporated. |
650 12 - SUBJECT ADDED ENTRY--TOPICAL TERM |
Topical term or geographic name entry element |
Drug Industry |
Geographic subdivision |
United States. |
|
Topical term or geographic name entry element |
Drug Industry |
General subdivision |
history |
Geographic subdivision |
United States. |
|
Topical term or geographic name entry element |
History, 20th Century |
Geographic subdivision |
United States. |
|
Topical term or geographic name entry element |
History, 21st Century |
Geographic subdivision |
United States. |
|
Topical term or geographic name entry element |
Technology, Pharmaceutical |
Geographic subdivision |
United States. |
906 ## - LOCAL DATA ELEMENT F, LDF (RLIN) |
a |
7 |
b |
cbc |
c |
orignew |
d |
1 |
e |
ecip |
f |
20 |
g |
y-gencatlg |
942 ## - ADDED ENTRY ELEMENTS (KOHA) |
Source of classification or shelving scheme |
|
Koha item type |
Book |
Suppress in OPAC |
No |